AEROSOL GENERATING SYSTEM COMPRISING A SOURCE OF DISTRIBUTION IMPROVEMENT COMPOUND AND A SOURCE OF D

专利摘要:
aerosol generating system comprising a delivery-enhancing compound source and a drug source. an aerosol generating system comprises a drug source (20) and a volatile delivery-enhancing compound source (10). the source of volatile distribution-enhancing compound (10) comprises a first sorption element (30), a second sorption element (40) downstream of the first sorption element (30), and a volatile delivery-enhancing compound sorbed on the the first sorption element (30) and the second sorption element (40), wherein the release rate of the volatile distribution enhancing compound from the first sorption element (30) is greater than the release rate of the improvement of volatile distribution from the second sorption element (40).
公开号:BR112015027149B1
申请号:R112015027149-9
申请日:2014-05-19
公开日:2022-01-11
发明作者:Alexandre Malgat
申请人:Philip Morris Products S.A.；
IPC主号:

专利说明:

[001] The present invention relates to an aerosol generating system and an aerosol generating article for use in an aerosol generating system. Specifically, the present invention relates to an aerosol generating system for generating an aerosol comprising nicotine salt particles and an aerosol generating article for use in such aerosol generating systems.
[002] WO 2008/121610 A1 , WO 2010/107613 A1 and WO 2011/034723 A1 disclose devices for delivering nicotine or other medicaments to a user that comprise a volatile acid, such as pyruvic acid, or other source of enhancing compound of volatile distribution, and a source of nicotine or other medications. The volatile delivery enhancing compound is reacted with the nicotine in the gas phase to form an aerosol of nicotine salt particles that is inhaled by the user.
[003] Figs. 2A-2C of WO 2010/107613 A1 illustrate an exemplary device with sequential configuration which is used in Experiment #8 of WO 2010/107613 A1. As shown in Figs. 2A-2C and described in paragraph [0052] and Experiment #8 of WO 2010/107613 A1, this experimental device comprises a tobacco source element 20 (moisture of wet tobacco packed between laminated stainless steel screen and Teflon outer casing ) and a pyruvic acid source element 30 (pyruvic acid in odorant plug) separated by a gap 60.
[004] It would be desirable to provide an aerosol generating system of the type disclosed in WO 2008/121610 A1, WO 2010/107613 A1 and WO 2011/034723 A1 wherein the delivery of nicotine salt particles to a user is improved. It would be especially desirable to provide an aerosol generating system of the type disclosed in WO 2008/121610 A1 , WO 2010/107613 A1 and WO 2011/034723 A1 in which the consistency of nicotine salt particles delivered to a user is improved.
[005] It would also be desirable to provide an aerosol generating system of the type disclosed in WO 2008/121610 A1, WO 2010/107613 A1 and WO 2011/034723 A1 which enables improved control of the delivery of nicotine salt particles to a user.
[006] In accordance with the invention, there is provided an aerosol generating system comprising: a drug source; and a source of volatile delivery-enhancing compound, the source of volatile delivery-enhancing compound comprising: a first sorption element; a second sorption element downstream of the first sorption element; and a volatile distribution-enhancing compound sorbed on the first sorption element and the second sorption element, wherein the release rate of the volatile delivery-enhancing compound from the first sorption element is greater than the rate of release of the volatile delivery-enhancing compound from the first sorption element. distribution improvement from the second sorption element.
[007] In accordance with the invention, there is also provided an aerosol generating system comprising: an aerosol generating article, the aerosol generating article comprising: a source of medicament; and a source of volatile delivery-enhancing compound, the source of volatile delivery-enhancing compound comprising: a first sorption element; a second sorption element downstream of the first sorption element; and a delivery-enhancing compound sorbed on the first sorption element and on the second sorption element, wherein the release rate of the volatile delivery-enhancing compound from the first sorption element is greater than the rate of release of the enhancement compound. of volatile distribution from the second sorption element.
[008] In accordance with the invention, there is further provided an aerosol generating system comprising: an aerosol generating article comprising: a drug source; and a source of volatile delivery-enhancing compound, the source of volatile delivery-enhancing compound comprising: a first sorption element; a second sorption element downstream of the first sorption element; and a volatile distribution-enhancing compound sorbed on the first sorption element and the second sorption element, wherein the rate of release of the volatile distribution-enhancing compound from the first sorption element is greater than the rate of release of the volatile delivery-enhancing compound from the first sorption element. volatile distribution enhancing compound from the second sorption element; and an aerosol generating device in cooperation with the aerosol generating article, the aerosol generating device comprising heating means for heating one or both of the source of volatile delivery-enhancing compound and the source of medicament the source of delivery-enhancing compound volatile distribution of the aerosol generating article.
[009] In accordance with the invention, there is additionally provided an aerosol generating article for use in an aerosol generating system in accordance with the invention, the aerosol generating article comprising: a source of medicament; and a source of volatile delivery-enhancing compound, the source of volatile delivery-enhancing compound comprising: a first sorption element; a second sorption element downstream of the first sorption element; and a delivery-enhancing compound sorbed on the first sorption element and on the second sorption element, wherein the release rate of the volatile delivery-enhancing compound from the first sorption element is greater than the rate of release of the enhancement compound. of volatile distribution from the second sorption element.
[0010] As used herein, the term "volatile" refers to a distribution-enhancing compound with a vapor pressure of at least about 20 Pa. Unless otherwise noted, all vapor pressures referred to in this document are vapor pressures at 25°C, measured in accordance with ASTM E119 4 - 07.
[0011] As used herein, by "sorbed" is meant that the volatile distribution enhancing compound is adsorbed onto the surface of the sorption element, or absorbed onto the sorption element, or adsorbed onto and absorbed onto the sorption element .
[0012] As used herein, the term "aerosol generating device" refers to a device that interacts with an aerosol generating article to generate an aerosol that is directly inhaled into a user's lungs through the user's mouth.
[0013] As used herein, the terms "downstream", "upstream", "proximal" and "distal" are used to describe the relative positions of components, or portions of components, of aerosol generating articles and systems. aerosol generators according to the invention.
[0014] The aerosol generating article or system comprises a proximal end through which, when in use, the aerosol leaves the aerosol generating article or system. The proximal end may also be referred to as the mouth end. When in use, a user draws on the proximal end, or mouth, of the aerosol generating article in order to inhale an aerosol generated by the system or aerosol generating article. The article or aerosol generating system comprises a distal end opposite the proximal, or mouth, end. The proximal or mouth end of the article or aerosol generating system may also be referred to as the downstream end and the distal end of the article or aerosol generating system may also be referred to as the upstream end. The components, or parts of the components, of the article or aerosol generating system may be described as being upstream or downstream of each other based on their relative positions between the proximal or downstream end and the distal or upstream end of the article. or aerosol generated system.
[0015] The upstream and downstream ends of the aerosol generating article are defined in relation to the airflow when a user inhales at the proximal, or mouth end, of the aerosol generating article. Air is drawn into the aerosol generating article at the distal or upstream end, passes downstream through the aerosol generating article and leaves the aerosol generating article at the proximal or downstream end.
[0016] As used in this document, the term "longitudinal" is used to describe the direction between the downstream or proximal end and the opposite upstream or distal end, and the term "transverse" is used to describe the direction perpendicular to the longitudinal direction.
[0017] The rate of release of the delivery-enhancing compound from the first sorption element of the source of the delivery-enhancing compound of aerosol generating systems according to the invention at a given temperature is greater than the rate of release of the compound delivery enhancement agent from the second sorption element of the delivery enhancement compound source of aerosol generating systems in accordance with the invention. As described further below, when in use, the inclusion of a source of delivery-enhancing compound that comprises a first sorption element and a second sorption element that releases the delivery-enhancing compound at different rates advantageously improves , the distribution of the drug to a user. In particular, the inclusion of a source of delivery-enhancing compound that comprises a first sorption element and a second sorption element that releases the delivery-enhancing compound at different rates advantageously improves the consistency of the measurement distribution. -call to a user.
[0018] The inclusion, in aerosol generating systems according to the invention, of a source of delivery-enhancing compound comprising a first sorption element and a second sorption element that releases the delivery-enhancing compound at different rates it may also advantageously enable improved control of drug delivery to a user.
[0019] Preferably, the release rate of the delivery-enhancing compound from the first sorption element is at least twice the rate of delivery of the delivery-enhancing compound from the second sorption element. Even more preferably, the rate of release of the delivery-enhancing compound from the first sorption element is at least three times greater than the rate of delivery of the delivery-enhancing compound from the second sorption element.
[0020] In certain embodiments, the rate of release of the distribution-enhancing compound from the first sorption element can vary between twice and ten times the rate of release of the distribution-enhancing compound from the second sorption element . In other embodiments, the rate of release of the delivery-enhancing compound from the first sorption element may vary between three times and ten times the rate of release of the delivery-enhancing compound from the second sorption element.
[0021] The air permeability of the first sorption element can be greater than the air permeability of the second sorption element. In such embodiments, the increased air permeability of the first sorption element, relative to the second sorption element, can increase the rate of release of the distribution-enhancing compound from the first sorption element relative to the release of the sorption compound. distribution improvement from the second sorption element.
[0022] Preferably, the air permeability of the first sorption element as measured in accordance with ISO 2965:2009 is at least 1.5 times greater than the air permeability of the second sorption element. More preferably, the air permeability of the first sorption element, as measured in accordance with ISO 2965:2009, is at least 2 times the air permeability of the second sorption element.
[0023] In certain embodiments, the air permeability of the first sorption element, as measured in accordance with ISO 2965:2009, can be between about 1.5 times and about 10 times greater than the air permeability of the second sorption element, preferably between about 1.5 times and about 5 times greater than the air permeability of the second sorption element. In other embodiments, the air permeability of the first element, as measured in accordance with ISO 2965:2009, can be between about 2 times to about 10 times greater than the air permeability of the second sorption element, preferably between about from 2 times to about 5 times the air permeability of the second sorption element.
[0024] In certain embodiments, the first sorption element may have an air permeability between about 250 Coresta units and about 300 Coresta units, as measured in accordance with ISO 2965:2009, and the second sorption element may have air permeability between about 100 Coresta units and about 150 Coresta units, as measured in accordance with ISO 2965:2009.
[0025] Air permeability in Coresta units is the amount of air in cubic centimeters that passes through one square centimeter of the sorption element in one minute at a constant pressure difference of one kilopascal (that is, 1 Coresta unit corresponds to at an air permeability of 1 cm3/min.cm2 at a pressure differential of 1 kPa).
[0026] As an alternative, or in addition to this, the porosity of the first sorption element may be greater than the porosity of the second sorption element. In such embodiments, the increased porosity of the first sorption element, relative to the second sorption element, may increase the rate of delivery of the delivery-enhancing compound from the first sorption element relative to the delivery of the delivery-enhancing compound to from the second sorption element.
[0027] Preferably, the air porosity of the first sorption element, as measured by mercury porosimetry, in accordance with ISO 15901-1:2005 is at least 1.5 times greater than the air porosity of the second sorption element . More preferably, the porosity of the first sorption element, as measured by mercury porosimetry, is at least twice as large as the porosity of the second sorption element.
[0028] In certain preferred embodiments, the first sorption element may have a porosity of between about 20% to about 50%, as measured by mercury porosimetry in accordance with ISO 15901-1:2005, and the second element Sorption can have porosity between about 5% and about 35%, al as measured by mercury porosimetry, in accordance with ISO 15901-1:2005.
[0029] In certain embodiments, the porosity of the first sorption element, as measured by mercury porosimetry in accordance with ISO 15901-1:2005, can be between about 1.5 times and about 10 times greater than porosity of the second sorption element, preferably between about 1.5 times to about 5 times greater than the porosity of the second sorption element. In other embodiments, the porosity of the first element, as measured by mercury porosimetry in accordance with ISO 15901-1:2005, can be between about 2 times to about 10 times greater than the porosity of the second sorption element, preferably from about 2 times to about 5 times the porosity of the second sorption element.
[0030] As an alternative or in addition to this, the polarity of the second sorption element may be greater than the polarity of the second sorption element. This is particularly preferred where the distribution enhancing compound is a polar compound. In such embodiments, the increased polarity of the second sorption element with respect to the first sorption element may decrease the rate of delivery of the delivery-enhancing compound from the second sorption element relative to the rate of delivery of the delivery-enhancing compound at from the first sorption element.
[0031] The second sorption element may be located immediately downstream of and in contact with the first sorption element.
[0032] Alternatively, the second sorption element may be spaced from the first sorption element.
[0033] Preferably, the volatile distribution enhancing compound has a vapor pressure of at least about 50 Pa, more preferably at least about 75 Pa, most preferably at least 100 Pa at 25°C.
[0034] Preferably, the volatile distribution enhancing compound has a vapor pressure of less than or equal to about 400, more preferably less than or equal to about 300 Pa, even more preferably less than or equal to about 275 Pa, most preferably less or equal to about 250 Pa at 25°C.
[0035] In certain embodiments, the volatile distribution enhancing compound may have a vapor pressure between about 20 Pa and about 400 Pa, more preferably between about 20 Pa and about 300 Pa, even more preferably between about 20 Pa. Pa and about 275 Pa, more preferably between about 20 Pa and about 250 Pa at 25°C.
[0036] In other embodiments, the volatile distribution enhancing compound may have a vapor pressure between about 50 Pa and about 400 Pa, more preferably between about 50 Pa and about 300 Pa, even more preferably between about 50 Pa and about 300 Pa, even more preferably between about 50 Pa and about 400 Pa. 50 Pa to about 275 Pa, more preferably from about 50 Pa to about 250 Pa at 25°C.
[0037] In further embodiments, the volatile distribution enhancing compound may have a vapor pressure between about 75 Pa and about 400 Pa, more preferably between about 75 Pa and about 300 Pa, even more preferably between about 75 Pa and about 300 Pa. 75 Pa to about 275 Pa, more preferably from about 75 Pa to about 250 Pa at 25°C.
[0038] In further embodiments, the volatile distribution enhancing compound may have a vapor pressure between about 100 Pa and about 400 Pa, more preferably between about 100 Pa and 300 Pa, even more preferably between about 100 Pa. Pa and about 275 Pa, more preferably between about 100 Pa and about 250 Pa at 25°C.
[0039] The volatile distribution enhancing compound may comprise a single compound. Alternatively, the volatile distribution enhancing compound may comprise two or more different compounds.
[0040] When the volatile distribution enhancing compound comprises two or more different compounds, the two or more different compounds combined have a vapor pressure of at least about 20 Pa at 25°C.
[0041] Preferably, the delivery-enhancing compound is a volatile liquid.
[0042] The volatile distribution enhancing compound may comprise a mixture of two or more different liquid compounds.
[0043] The volatile distribution enhancing compound may comprise an aqueous solution of one or more compounds. The volatile distribution enhancing compound may comprise a non-aqueous solution of one or more compounds.
[0044] The volatile distribution enhancing compound may comprise two or more different volatile compounds. For example, the volatile distribution enhancing compound may comprise a mixture of two or more compounds from different volatile liquids.
[0045] Alternatively, the volatile distribution enhancing compound may comprise one or more non-volatile compounds and one or more volatile compounds. For example, the volatile distribution enhancing compound may comprise a solution of one or more non-volatile compounds in a volatile solvent or a mixture of one or more non-volatile liquid compounds and one or more volatile liquid compounds.
[0046] In one embodiment, the volatile distribution enhancing compound comprises an acid. The volatile distribution enhancing compound may comprise an organic acid or an inorganic acid. Preferably, the volatile distribution enhancing compound comprises an organic acid, more preferably a carboxylic acid, most preferably an alpha-keto or 2-oxo acid.
[0047] In a preferred embodiment, the volatile distribution enhancing compound comprises an acid selected from the group consisting of 3-methyl-2-oxopentanoic acid, pyruvic acid, 2-oxopentanoic acid, 4-methyl-2-oxopentanoic acid , 3-methyl-2-oxobutanoic acid, 2-oxo-octanoic acid and combinations thereof. In a particularly preferred embodiment, the volatile distribution enhancing compound comprises pyruvic acid.
[0048] Preferably, the distribution-enhancing compound is adsorbed onto the first sorption element and the second sorption element.
[0049] The first sorption element and the second sorption element act as reservoirs for the volatile distribution enhancing compound.
[0050] The first sorption element and the second sorption element can be formed from the same material or from different materials.
[0051] The first sorption element and the second sorption element may be formed from any suitable material or combination of materials. For example, the first sorption element and the second sorption element may comprise one or more of glass, stainless steel, aluminum, polyethylene (PE), polypropylene, polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE) and BAREX®.
[0052] In a preferred embodiment, at least one of the first and second sorption elements is a porous sorption element.
[0053] For example, at least one of the first and second sorption elements may be a porous sorption element comprising one or more materials selected from the group consisting of porous plastic materials, porous polymeric fibers and glass fibers porous.
[0054] In a particularly preferred embodiment, both the first sorption element and the second sorption element are porous sorption elements.
[0055] The first element and the second sorption element are preferably chemically inert with respect to the volatile distribution enhancing compound.
[0056] The first sorption element and the second sorption element can have any suitable shape and dimensions.
[0057] The first sorption element and the second sorption element can have the same shape and the same dimension, or different shapes and dimensions. Preferably, the first sorption element and the second sorption element are of substantially shape and size.
[0058] In a preferred embodiment, at least one of the first and second sorption elements is cylindrical plug. In a preferred embodiment, at least one of the first sorption element and the second sorption element is a substantially cylindrical porous plug. In a particularly preferred embodiment, both the first sorption element and the second sorption element are substantially cylindrical porous plugs.
[0059] In another embodiment, at least one of a first sorption element and the second sorption element is a substantially cylindrical hollow tube. In another preferred embodiment, at least one of the first sorption element and the second sorption element is a substantially cylindrical porous hollow tube.
[0060] The size, shape and composition of the first sorption element and the second sorption element can be chosen so as to enable a desired amount of the volatile distribution enhancing compound to be sorbed on the first sorption element and the second sorption element.
[0061] Preferably, the source of delivery-enhancing compound comprises a total of between about 200 µl and about 600 µl, more preferably between about 250 µl and about 550 µl, more preferably between about 300 µl and about of 500 μl of the volatile distribution enhancing compound.
[0062] The first sorption element and the second sorption element act as reservoirs for the volatile distribution enhancing compound.
[0063] Preferably, the amount of the volatile delivery-enhancing compound adsorbed on the first sorption element is greater than an amount of the delivery-enhancing compound adsorbed on the second sorption element. In such embodiments, the first sorption element advantageously acts as a major reservoir of the volatile delivery enhancing compound and the second sorption element serves as a minor reservoir of the volatile delivery enhancing compound.
[0064] Preferably, at least about 150 µl, more preferably at least about 200 µl, most preferably at least about 250 µl of the volatile distribution-enhancing compound is sorbed on the first sorption element.
[0065] For example, between about 150 µl and about 450 µl, more preferably between about 200 µl and about 400 µl, most preferably between about 225 µl and about 375 µl of the distribution enhancing compound volatile can be sorbed on the first sorption element.
[0066] Preferably, at least about 20 µl, more preferably at least about 50 µl, most preferably at least about 75 µl of the volatile distribution enhancing compound is sorbed on the second sorption element.
[0067] For example, between about 20 µl and about 200 µl, more preferably between about 50 µl and about 150 µl, most preferably between about 75 µl and about 125 µl of the distribution enhancing compound volatile can be sorbed on the second sorption element.
[0068] The drug source preferably comprises a drug with a melting point below about 150 degrees Celsius. Alternatively, or in addition to this, the medicament preferably has a boiling point below 300 degrees Celsius.
[0069] In certain preferred embodiments, the medicament comprises one or more saturated or unsaturated aliphatic or aromatic nitrogen bases (alkaline nitrogen-containing compounds) in which the nitrogen atom is present in a heterocyclic ring or in a chain. acyclic (replacement).
[0070] The medicament may comprise one or more compounds selected from a group consisting of: nicotine; 7-Hydroxymitragynine; Arecoline; Atropine; Bupropion; Catine (D-norpseudoephedrine); Chlorpheneramine; Dibucaine; Dimemorphan, Dimethyltryptamine, Diphenhydramine, Ephedrine, Hordenine, Hyoscyamine, Isoarecholine, Levorphanol, Lobeline, Mesembrine, Mitragynine, Muscatine, Procaine, Pseudoephedrine, Pyrilamine, Racloprid, Ritodrine, Scopolamine, Sparteine (Lupinidine) and Ticlopidine; tobacco smoke constituents such as Tetrahydroisoquinolines 1,2,3,4, Anabasine, Anatabine, Cotinine, Myosmin, Nicotrin, Norcotinine and Nornicotine; anti-asthmatic drugs such as Orciprenaline, Propranolol and Terbutaline; antianginal drugs such as Nicorandil, Oxprenolol and Verapamil; antiarrhythmia drugs such as Lidocaine; nicotinic agonists such as Epibatidine, 5-(2R)-azetidinylmethoxy)-2-chloropyridine (ABT-594), (S)-3-methyl-5-(1-methyl-2-pyrolidinyl)isoxazole (ABT 418) and (±)-2-(3-Pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429); nicotinic antagonists such as Methylcotinine and Mecamylamine; acetyl cholinesterase inhibitors such as Galantamine, Pyridostigmine, Physostigmine and Tacrine; and MAO inhibitors such as Methoxy-N, N-dimethyltryptamine, 5-methoxy-α-methyltryptamine, Alpha-methyltryptamine, Iproclozid, Iproniazid, Isocarboxazide, Linezolid, Meclobemide, N, N - Dimethyltryptamine, Phenelzine, Phenyl-ethylamine , Toloxatone, Tranylcypromine and Tryptamine.
[0071] In preferred embodiments, the drug source is a nicotine source.
[0072] The nicotine source may comprise one or more of nicotine, nicotine base, a nicotine salt, such as nicotine-HCl, nicotine bitartrate or nicotine ditartrate or a nicotine derivative.
[0073] The source of nicotine may comprise natural nicotine or synthetic nicotine.
[0074] The nicotine source may comprise pure nicotine, a solution of nicotine in an aqueous or non-aqueous solvent or a liquid tobacco extract.
[0075] The source of nicotine may further comprise an electrolyte forming compound. The electrolyte forming compound may be selected from the group consisting of alkali metal hydroxides, alkali metal oxides, alkali metal salts, alkaline earth metal oxides, alkaline earth metal hydroxides and combinations thereof.
[0076] For example, the nicotine source may comprise an electrolyte forming compound selected from the group consisting of potassium hydroxide, sodium hydroxide, lithium oxide, barium oxide, potassium chloride, sodium chloride, carbonate sodium, sodium citrate, ammonium sulfate and combinations thereof.
[0077] In certain embodiments, the nicotine source may comprise an aqueous nicotine solution, nicotine base, a nicotine salt or nicotine derivative, and an electrolyte-forming compound.
[0078] Alternatively, or in addition to this, the nicotine source may additionally comprise other components including, but not limited to, natural flavors, artificial flavors and antioxidants.
[0079] The drug source may comprise a third sorption element and a drug sorbed on the third sorption element. In preferred embodiments where the drug source is a nicotine source, the nicotine source may comprise a third element and nicotine sorbed on the third sorption element.
[0080] The third sorption element acts as a reservoir for nicotine or other medication.
[0081] The third sorption element can be formed from the same or different materials of the first sorption element and the second element of materials.
[0082] The third sorption element may be formed from any suitable material or combination of materials. For example, the third sorption element may comprise one or more of glass, stainless steel, aluminum, polyethylene (PE), polypropylene, polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (eP-TFE) and BAREX®.
[0083] In a preferred embodiment, the third sorption element is a porous sorption element.
[0084] For example, the third sorption element may be a porous sorption element comprising one or more materials selected from a group consisting of porous plastic materials, porous polymeric fibers and porous glass fibers.
[0085] The third sorption element is preferably chemically inert with respect to nicotine or another drug.
[0086] The third sorption element can be of any suitable size and shape.
[0087] The third sorption element may have the same or different shape and dimensions of the shape and dimensions of the first sorption element and the second sorption element.
[0088] In one embodiment, the third sorption element is a cylindrical plug. In a preferred embodiment, the third sorption element is a substantially cylindrical porous plug.
[0089] In another preferred embodiment, the third sorption element is a substantially cylindrical hollow tube. In another preferred embodiment, the third sorption element is a substantially cylindrical hollow tube.
[0090] The size, shape and composition of the third sorption element can be chosen so as to enable a desired amount of nicotine or any other drug to be sorbed onto the third sorption element.
[0091] Preferably, the drug source comprises between about 10 µl and about 300 µl, more preferably between about 20 µl and about 200 µl, most preferably between about 50 µl and about 250 µl of the nicotine or another medicine.
[0092] In a preferred embodiment, the aerosol generating system comprises: an aerosol generating article comprising the drug source and the volatile delivery-enhancing compound source.
[0093] Preferably, the aerosol generating article comprises: a first compartment comprising a first of the drug source and the volatile delivery-enhancing compound source; and a second compartment comprises a second of the drug source and the volatile delivery-enhancing compound source.
[0094] Preferably, the first compartment comprises the source of volatile delivery enhancing compound and the second compartment comprises the source of medicament. However, it should be understood that the first compartment may alternatively comprise the drug source and the second drug may alternatively comprise the source of volatile delivery-enhancing compound.
[0095] The first compartment and the second compartment of the aerosol generating article may be adjacent to each other. Alternatively, the first compartment and the second compartment of the aerosol generating article may be spaced apart.
[0096] The first compartment of the aerosol generating article may be sealed by one or more frangible barriers. In a preferred embodiment, the first compartment is sealed by a pair of opposing transverse frangible barriers.
[0097] Alternatively, or in addition to this, the second compartment of the aerosol generating article may be sealed by one or more frangible barriers. In a preferred embodiment, the second compartment is sealed by a pair of opposing transverse frangible barriers.
[0098] The one or more frangible barriers may be formed from any suitable material. For example, the one or more frangible barriers may be formed from a foil or foil.
[0099] The volumes of the first compartment and the second compartment can be the same or different from each other. In a preferred embodiment, the volume of the second compartment is greater than the volume of the first compartment.
[00100] As described in more detail below, the first compartment and the second compartment may be arranged in series or parallel within the aerosol generating article.
[00101] As used herein, "serial" is understood to mean that the first compartment and the second compartment are arranged within the aerosol generating article so that, when in use, the flow of air drawn through the aerosol generating article passes through one of the first compartment and the second compartment, then passes through the other of the first compartment and the second compartment.
[00102] In embodiments where the first compartment comprises the volatile delivery-enhancing compound and the second compartment comprises the drug source, vapor of the volatile delivery-enhancing compound is released from the source of delivery-enhancing compound into the drug. first compartment into the air stream engulfed through the aerosol generating article and the drug vapor is released from the drug source into the second compartment in the air stream engulfed through the aerosol generating article. The volatile delivery-enhancing compound vapor reacts with the drug vapor in the gas phase to form an aerosol, which is delivered to a user.
[00103] In embodiments where the first compartment comprises the drug source and the second compartment comprises the volatile delivery-enhancing compound source, the drug vapor is released from the drug source into the first compartment within the air stream inhaled through the aerosol-generating article and the vapor of the volatile delivery-enhancing compound is released from the source of volatile delivery-enhancing compound in the second compartment within the air stream engulfed through the aerosol-generating article. The drug vapor reacts with the volatile delivery-enhancing compound vapor in the gas phase to form an aerosol, which is delivered to a user.
[00104] Where the first compartment and the second compartment are arranged in series within the aerosol generating article, the second compartment is preferably located downstream of the first compartment so that, when in use, a flow of air is engulfed through of the aerosol generating article passes through the first compartment and then passes through the second compartment. However, it should be noted that the second compartment may alternatively be located upstream of the first compartment so that, when in use, a stream of air drawn in through the aerosol generating article passes through the second compartment and, in then through the first compartment.
[00105] In embodiments where the second compartment is downstream of the first compartment, the volatile delivery-enhancing compound vapor may react with the medicament vapor in the second compartment. In such embodiments, the aerosol generating article may additionally comprise a third compartment downstream of the second compartment and the vapor of volatile delivery-enhancing compound may, alternatively or in addition to this, react with the vapor of the medicament in the third compartment to form an aerosol.
[00106] In embodiments where the second compartment is upstream of the first compartment, the vapor of the volatile delivery-enhancing compound may react with the vapor of medicament in the first compartment. In such embodiments the aerosol generating article may further comprise a third component downstream of the first compartment and the vapor of volatile delivery enhancing compound may, alternatively or in addition to this, react with the medicament vapor in the third compartment to form a aerosol.
[00107] As used herein, "parallel" is understood to mean that the first compartment and the second compartment are arranged within the aerosol generating article so that, when in use, a first stream of air is drawn through of the aerosol generating article passes through the first compartment and a second stream of air engulfed through the aerosol generating article passes through the second compartment.
[00108] In embodiments where the first compartment comprises the source of volatile delivery enhancement compound and the second compartment comprises the source of drug, vapor of volatile delivery enhancement compound is released from the source of drug delivery enhancement compound. volatile delivery in the first compartment into the first stream of air engulfed through the aerosol generating article and the medicament vapor is released from the source of medicament in the second compartment into the second stream of air engulfed through the aerosol generating article. aerosol. The volatile delivery-enhancing compound vapor in the first air stream reacts with the drug vapor in the second air stream in the gas phase to form an aerosol, which is then delivered to a user.
[00109] In such embodiments, the aerosol generating article may further comprise a third component downstream of the first compartment and the second compartment, and the vapor of the volatile delivery-enhancing compound in the first air stream may mix with and react with the medicament vapor in the second air stream in the third compartment to form an aerosol.
[00110] In embodiments where the first component comprises the drug source and the second compartment comprises the volatile delivery-enhancing compound source, drug vapor is released from the drug source in the first compartment into the first compartment. flow of air engulfed through the aerosol generating article, and the vapor of volatile delivery enhancement compound is released from the source of volatile delivery enhancement compound in the second compartment into the second air stream engulfed through the generating article of aerosol. The drug vapor in the first air stream reacts with the volatile delivery-enhancing compound vapor in the second air stream in the gas phase to form an aerosol, which is then delivered to a user.
[00111] In such embodiments, the aerosol generating article may further comprise a third component downstream of the first compartment and the second compartment and the medicament vapor in the first air stream may mix with and react with the vapor of the compound. of volatile delivery enhancement in the second air stream in the third compartment to form an aerosol.
[00112] In particularly preferred embodiments, the aerosol generating article comprises: a housing comprising: an air inlet; a first compartment in communication with the air inlet, the first compartment comprising a first of the drug source and the volatile delivery-enhancing compound source; a second compartment in communication with the first compartment, the second compartment comprising a second of the volatile delivery-enhancing compound source and the drug source; and an air outlet, wherein the air inlet and air outlet are in communication with each other and configured so that air can pass into the housing through the air inlet, through the housing and out of the housing through the air outlet.
[00113] As used herein, the term "air inlet" is used to describe one or more openings through which air could be drawn into the aerosol generating article.
[00114] As used herein, the term "air outlet" is used to describe one or more openings through which air can be drawn out of the aerosol generating article.
[00115] In such embodiments, the first compartment and the second compartment are arranged in series from the air inlet to the air outlet inside the housing. That is, the first compartment is downstream of the air inlet, the second compartment is downstream of the first compartment and the air outlet is downstream of the second compartment. When in use, a stream of air is drawn into the housing through the air inlet downstream through the first compartment and the second compartment and out of the housing through the air outlet.
[00116] The aerosol generating article may further comprise a third compartment in communication with: the second compartment and the air outlet. During use in such embodiments, a flow of air is drawn into the housing through the air inlet, downstream through the first compartment, the second compartment and the third compartment, and out of the housing through the air outlet.
[00117] The aerosol generating article may additionally comprise a mouthpiece in communication with: the second compartment or the third compartment, where present; and the air outlet. During use in such embodiments, a stream of air is drawn into the housing through the air inlet, downstream through the first compartment, the second compartment, the third compartment, where present, and the nozzle and out of the housing. through the air outlet.
[00118] In other preferred embodiments, the aerosol generating article comprises: a housing comprising: an air inlet; a first compartment in communication with the air inlet, the first compartment comprising a first of the drug source and the volatile delivery-enhancing compound source; a second compartment in communication with the air inlet, the second compartment comprising a second drug source and the volatile delivery-enhancing compound source; and an air outlet, wherein the air inlet and air outlet are in communication with each other and configured so that air can pass into the housing through the air inlet, through the housing and out of the housing through the air outlet.
[00119] In such embodiments, the first compartment and the second compartment are arranged in parallel from the air inlet to the air outlet inside the housing. The first compartment and the second compartment are both downstream of the air inlet and upstream of the air outlet. During use, an airflow is drawn into the housing through the air inlet, a first part of the airflow is drawn downstream through the first compartment and a second part of the airflow is drawn downstream through the second compartment.
[00120] The aerosol generating article may further comprise a third compartment in communication with: the first compartment and/or the second compartment; and the air outlet.
[00121] The aerosol generating article may further comprise a nozzle in communication with: the first compartment and the second compartment, or the third compartment, when present; and the air outlet.
[00122] In further preferred embodiments, the aerosol generating article comprises: a housing comprising: a first air inlet; a second air inlet; a first compartment in communication with the first air inlet, the first compartment comprising a first source of volatile delivery-enhancing compound and a first source of medicament; a second compartment in communication with the second air inlet, the second compartment comprising a second source of volatile delivery-enhancing compound and a second source of medicament; and an air outlet, wherein the first air inlet, the second air inlet and the air outlet are in communication with each other and configured so that air can pass into the housing through the first air inlet, through the housing and out of the housing through the air outlet and the air can pass into the housing through the second air inlet, through the housing and out of the housing through the air outlet.
[00123] In such embodiments, the first compartment and the second compartment are arranged in parallel within the housing. The first compartment is downstream of the first air inlet and upstream of the air outlet and the second compartment is downstream of the second air inlet and upstream of the air outlet. During use, the first air stream is drawn into the housing through the first air inlet and downstream through the first compartment and a second air flow is drawn into the housing through the second air inlet and the downstream through the second compartment.
[00124] The aerosol generating article may further comprise a third compartment in communication with: the first compartment and/or the second compartment; and the air outlet.
[00125] The aerosol generating article may further comprise a nozzle in communication with: the first compartment and the second compartment, or the third compartment, when present; and the air outlet.
[00126] The housing of the aerosol generating article can simulate the shape and dimensions of a tobacco smoking article, such as a cigarette, cigar, cigarillo or pipe, or a pack of cigarettes. In a preferred embodiment, the housing simulates the shape and dimensions of a cigarette.
[00127] When present, the third compartment may comprise one or more aerosol modifying agents. For example, the third compartment may comprise an adsorbent, such as activated carbon, a flavorant, such as menthol, or a combination thereof.
[00128] When present, the mouthpiece may comprise a filter. The filter may have low particulate filtration efficiency or very low particulate filtration efficiency. Alternatively, the mouthpiece may comprise a hollow tube.
[00129] In a preferred embodiment, the aerosol generating system comprises: an aerosol generating article comprising the drug source and the volatile delivery-enhancing compound source; and an aerosol generating device in cooperation with the aerosol generating article, the aerosol generating device comprising heating means for heating one or both of the drug source and the delivery-enhancing compound source of the aerosol generating article.
[00130] The aerosol generating device preferably comprises a cavity configured to receive at least a portion of the aerosol generating article.
[00131] In embodiments wherein the aerosol generating article comprises: a first compartment comprising a first source of medicament and a first source of volatile delivery-enhancing compound; and a second compartment comprising a second source of medicament and a second source of volatile delivery-enhancing compound, the aerosol generating device preferably comprises a cavity configured to receive the first compartment and the second compartment of the aerosol generating article.
[00132] Preferably, the cavity of the aerosol generating device is substantially cylindrical.
[00133] The cavity of the aerosol generating device may have a cross-section of any suitable shape. For example, the cavity may have a substantially circular, elliptical, triangular, square, rhomboid, trapezoidal, pentagonal, hexagonal, or octagonal diagonal cross-section.
[00134] As used in this document, the term "diagonal cross section" is used to describe the cross section of the cavity perpendicular to the main axis of the cavity.
[00135] Preferably, the cavity of the aerosol generating device has a diagonal cross section substantially identical in shape to the diagonal cross section of the aerosol generating article.
[00136] In certain embodiments, the cavity of the aerosol generating device may have a diagonal cross section of substantially the same shape and dimensions as the diagonal cross section of the aerosol generating article to be received in the cavity in order to maximize conductive heat transfer from the aerosol generating device to the aerosol generating article.
[00137] Preferably, the cavity of the aerosol generating device has a substantially circular diagonal cross-section or a substantially elliptical diagonal cross-section. More preferably, the cavity of the aerosol generating device has a substantially circular diagonal cross-section.
[00138] Preferably, the length of the cavity of the aerosol generating device is less than the length of the aerosol generating article so that when the aerosol generating article is received in the cavity of the aerosol generating device, the proximal or downstream end of the aerosol generating article projects out of the cavity of the aerosol generating device.
[00139] As used herein, "length" is understood to mean the maximum longitudinal dimension between the distal or upstream end and the proximal or downstream end of the cavity and the aerosol generating article.
[00140] Preferably, the cavity of the aerosol generating device has a diameter substantially equal to or slightly greater than the diameter of the aerosol generating article.
[00141] As used herein, "diameter" is the maximum transverse dimension of the cavity and the aerosol generating article.
[00142] In embodiments where the first compartment and/or the second compartment of the aerosol generating article is sealed by one or more frangible seals, the aerosol generating device may further comprise a piercing member positioned within the cavity to pierce the first and second compartments of the aerosol generating article. The piercing element may be formed from any suitable material.
[00143] Where the first compartment and the second compartment of the aerosol generating article are arranged in series within the aerosol generating article, the piercing element is preferably positioned centrally within the cavity of the aerosol generating device, at the along the main axis of the cavity.
[00144] Where the first compartment and the second compartment of the aerosol generating article are arranged in parallel within the aerosol generating article, the piercing element may comprise a first piercing element within the cavity of the aerosol generating device for puncturing the first compartment of the aerosol generating article and a second piercing member positioned within the cavity of the aerosol generating device for puncturing the second compartment of the aerosol generating article.
[00145] The aerosol generating device comprises heating means for heating the drug source and/or the delivery-enhancing compound source of the aerosol generating article.
[00146] The heating means may be non-electrical heating means.
[00147] In certain embodiments, the heating means may comprise a heat sink or heat exchanger configured to transfer thermal energy from a heat source external to the drug source and/or the volatile delivery-enhancing compound source of the aerosol generating article. The heat sink or heat exchanger may be formed from any suitable thermally conductive material. Suitable materials include, but are not limited to, metals such as aluminum and copper.
[00148] In certain embodiments, the heating means may comprise a heat sink or heat exchanger configured to transfer thermal energy from a blue flame or torch lighter or any other type of lighter to the drug source and/or the source. of volatile delivery enhancing compound of the aerosol generating article. In such embodiments, a user may advantageously use a lighter to activate the aerosol generating system in a manner similar to lighting a cigarette or other conventional smoking article.
[00149] The heat sink or heat exchanger may extend fully or partially along the cavity of the aerosol generating device.
[00150] Alternatively, the heating means may be electrical heating means powered by an electrical power source.
[00151] Where the heating means are electrical heating means, the aerosol generating device may further comprise an electrical power source and a controller comprising electronic circuits configured to control the supply of electrical power from the power source to the electrical heating means. Any suitable electronic circuit may be used in order to control the power source for the electrical heating means. The electronic circuit can be programmable.
[00152] Alternatively, the electrical heating means may be powered by an external electrical power source.
[00153] The electrical power source may be a DC voltage source. In preferred embodiments, the source of electrical energy is a battery. For example, the source of electrical energy may be a nickel-metal hydride battery, a nickel-cadmium battery, or a lithium-based battery, for example, a lithium-cobalt, lithium-iron-phosphate, or lithium-iron-phosphate battery. polymer lithium battery. The source of electrical energy may alternatively be any form of electrical charge storage device, such as a capacitor. The electrical power source may require recharging and may have a capacity that allows sufficient electrical energy to be stored for use by the aerosol generating device with one or more aerosol generating articles.
[00154] The aerosol generating device may comprise a heating means comprising one or more heating elements. The one or more heating elements may extend fully or partially along the length of the cavity of the aerosol generating device. The one or more heating elements may extend fully or partially around the circumference of the cavity of the aerosol generating device.
[00155] The aerosol generating device may further comprise a controller configured to independently control a power source to the one or more heating elements.
[00156] In a preferred embodiment, the heating means comprises one or more heating elements that are electrically heated. However, other heating schemes can be used to heat the one or more heating elements. For example, the one or more heating elements can be heated by conducting another heat source. Alternatively, the one or more heating elements may be infrared heating elements or inductive heating elements.
[00157] In a particularly preferred embodiment, the heating means comprise one or more heating elements comprising an electrically resistive material. Each heating element may comprise an inelastic material, for example a sintered ceramic material such as alumina (Al2O3) and silicon nitride (Si3N4), or printed circuit board or silicon rubber. Alternatively, each heating element may comprise an elastic material, metallic material, for example an iron alloy or a nickel-chromium alloy. The one or more heating elements may be flexible heating sheets on a dielectric substrate, such as polyimide. Alternatively, the one or more heating elements may be metal grid or grids, flexible printed circuit boards or flexible carbon fiber heaters.
[00158] Other electrically resistive materials include, but are not limited to: semiconductors such as doped ceramics, electrically "conductive" ceramics (such as, for example, molybdenum disilicate), carbon, graphite, metal and metal alloys, and composite materials made from a ceramic material and a metallic material. Such composite materials may comprise doped or undoped ceramics. Examples of suitable doped ceramics include doped silicon carbides. Examples of suitable metals include titanium, zirconium, tantalum and platinum group metals. Examples of suitable metal alloys include stainless steel, nickel, cobalt, chromium, aluminum, titanium, zirconium, hafnium, niobium, molybdenum, tantalum, tungsten, tin, gallium and manganese-based superalloys, and superalloys based on nickel, iron, cobalt, stainless steel, Timetal® and ferro-manganese-aluminium-based alloys. Timetal® is a registered trademark of Titanium Metals Corporation, 1999 Broadway Suite 4300, Denver, Colorado. In composite materials, the electrically resistive material may optionally be embedded in, encapsulated in or coated with insulating material or vice versa, depending on the energy transfer kinetics and external physicochemical properties required.
[00159] The aerosol generating device may further comprise a temperature sensor configured to sense the temperature of the aerosol generating device.
[00160] In such embodiments, the aerosol generating device may comprise a controller configured to control a power source for one or more heating elements based on the temperature of the aerosol generating article detected by the temperature sensor.
[00161] The heating means may comprise one or more heating elements formed from a metal with a defined relationship between temperature and resistivity. In such embodiments, the metal may be formed as a rail between two layers of suitable insulating materials. Heating elements formed in this way can be used both to heat and to monitor the temperature of the aerosol generating article.
[00162] The aerosol generating device may additionally comprise a housing containing the cavity, the heating means and, where present, controller and power source.
[00163] Preferably, the housing of the aerosol generating device is substantially cylindrical.
[00164] The housing of the aerosol generating device may be designed to be pinched or held by a user.
[00165] In a preferred embodiment, the aerosol generating device is a cylindrical heating sleeve.
[00166] For the avoidance of doubt, the features described above in relation to one aspect of the invention may also be equally applicable to other aspects of the invention. In particular, features described above with respect to aerosol generating systems according to the invention may also refer, where appropriate, to aerosol generating articles according to the invention, and vice versa.
[00167] The invention will be described below with reference to the accompanying figures, in which: Figure 1(a) illustrates a schematic longitudinal cross-section of an aerosol generating article comprising a source of medicament and a source of drug-enhancing compound. delivery of the type disclosed in WO 2008/121610 A1 and WO 2010/107613 A1.a Figure 1(b) illustrates a schematic longitudinal cross-section of an aerosol generating article comprising a drug source and a delivery-enhancing compound source according to a first embodiment of the invention; Figure 1(c) illustrates a schematic longitudinal cross-section of an aerosol generating article comprising a source of medicament and a source of delivery-enhancing compound of the type disclosed in accordance with a second embodiment of the invention; Figure 2 shows the distribution of nicotine per puff as a function of the number of puffs for aerosol generating articles according to: comparative example (a); example (b); and example (c) when heating measured under a Health Canada smoking regimen; Figure 3 shows the distribution of nicotine per puff as a function of the number of puffs for aerosol generating articles according to: example (b); example (d); and example (e) when heating measured under a Health Canada smoking regimen; Figure 4 shows the distribution of nicotine per puff as a function of the number of puffs for aerosol generating articles according to: example (b); example (f); and example (g) when heating measured under a Health Canada smoking regimen.
[00168] The prior art aerosol generating article shown in Figure 1(a) comprises a source of pyruvic acid (10) and a source of nicotine (20). As shown in Figure 1(a), the pyruvic acid source (10) and the nicotine source (20) are arranged in series with the nicotine source (20) downstream of and spaced from the pyruvic acid source (10). ). The pyruvic acid source (10) comprises a porous sorption element (30) with pyruvic acid sorbed thereon and the nicotine source (20) comprises a porous sorption element (50) with nicotine sorbed thereto.
[00169] The aerosol generating article according to the first embodiment shown in Figure 1(b) also comprises a pyruvic acid source (10) and a nicotine source (20) arranged in series with the nicotine source (20) downstream of and spaced from the source of pyruvic acid (10). However, the aerosol generating article according to the first embodiment of the invention shown in Figure 1(b) differs from the prior art aerosol generating article shown in Figure 1(a) in that the source of pyruvic acid (10) comprises a first porous sorption element (30) with pyruvic acid sorbed thereon and a second porous sorption element (40) with pyruvic acid sorbed thereon. As shown in Figure 1(b), the first sorption element (30) and the second porous sorption element (40) arranged in series with the second porous sorption element (40) immediately downstream of and abutting the first porous sorption element (30).
[00170] The aerosol generating article according to the second embodiment of the invention shown in Figure 1(b) is similar in construction to the aerosol generating article according to the first embodiment shown in Figure 1(b). However, in the aerosol generating article according to the second embodiment shown in Figure 1(b) the second porous sorption element (40) of the pyruvic acid source (10) is located downstream of and spaced from the first sorption element. porous sorption (30) of the pyruvic acid source (10). Comparative example (a)
[00171] To form a source of pyruvic acid, 500 μl of pyruvic acid is sorbed via capillarity into a sintered porous plastic plug with a length of 20 mm and a density of 0.33g/cm3, having a core of polyethylene terephthalate (PET) and a polyethylene (PE) sheath. A suitable porous plastic plug is Porex® XMF-0507 (available from Porex® Technologies GmbH, Germany).
[00172] To form a source of nicotine, 10 μl of nicotine is sorbed by means of capillarity in a sintered porous plastic plug with a length of 50 mm and a density of 0.33 g/cm3, having a core of polyethylene terephthalate ( PET) and a polyethylene (PE) sheath. A suitable porous plastic plug is Porex® XMF-0507 (available from Porex® Technologies GmbH, Germany).
[00173] A prior art aerosol generating article with construction as shown in Figure 1(a) is assembled comprising the source of pyruvic acid and the source of nicotine. The nicotine source is positioned 10 mm downstream from the pyruvic acid source. Example (b)
[00174] To form a source of pyruvic acid 250 μl of pyruvic acid are wick sorbed into a first sintered porous plastic plug with a length of 10 mm and a density of 0.33g/cm3 having a core of polyethylene terephthalate (PET) ) and a polyethylene (PE) sheath and 100 μl of pyruvic acid are sorbed by capillarity into a second sintered porous plastic plug with a length of 10 mm and a density of 0.33g/cm3 with a core of polyethylene terephthalate (PET) and a sheath of polyethylene terephthalate (PET) and lower air permeability than the first sintered porous plug. A suitable plastic first porous plug is Porex® XMF-0507 (available from Porex GmbH, Germany) and a suitable second plastic porous plug is Porex® XMF-0607 (available from Porex GmbH, Germany).
[00175] To form a source of nicotine, 10 μl of nicotine is sorbed by means of capillarity into a sintered porous plastic plug with a length of 50 mm and a density of 0.33 g/cm3, having a core of polyethylene terephthalate ( PET) and a polyethylene (PE) sheath. A suitable porous plastic plug is Porex® XMF-0507 (available from Porex® Technologies GmbH, Germany).
[00176] An aerosol generating article according to the invention, with construction as shown in Figure 1(b) is assembled comprising the source of pyruvic acid and the source of nicotine. The second sintered plastic pyruvic acid source plug is positioned immediately downstream of and abutting the first sintered plastic pyruvic acid source plug and the nicotine source is positioned 10 mm downstream of the second plastic plug porous sinter from the source of pyruvic acid.
[00177] To form a source of pyruvic acid 250 μl of pyruvic acid are wick sorbed into a first sintered porous plastic plug with a length of 10 mm and a density of 0.33g/cm3 having a core of polyethylene terephthalate (PET) ) and a polyethylene (PE) sheath and 100 μl of pyruvic acid are sorbed by capillarity into a second sintered porous plastic plug with a length of 10 mm and a density of 0.33g/cm3 with a core of polyethylene terephthalate (PET) and a sheath of polyethylene terephthalate (PET) and lower air permeability than the first sintered porous plug. A suitable plastic first porous plug is Porex® XMF-0507 (available from Porex GmbH, Germany) and a suitable second plastic porous plug is Porex® XMF-0607 (available from Porex GmbH, Germany).
[00178] To form a source of nicotine, 10 μl of nicotine is sorbed by means of capillarity into a sintered porous plastic plug with a length of 50 mm and a density of 0.33 g/cm3, having a core of polyethylene terephthalate ( PET) and a polyethylene (PE) sheath. A suitable porous plastic plug is Porex® XMF-0507 (available from Porex® Technologies GmbH, Germany).
[00179] An aerosol generating article according to the invention, with construction as shown in Figure 1(b) is assembled comprising the source of pyruvic acid and the source of nicotine. The second sintered plastic plug of the pyruvic acid source is positioned 2 mm downstream of the first porous plastic sintered plug of the pyruvic acid source and the nicotine source is positioned 10 mm downstream of the second porous plastic sintered plug from the source of pyruvic acid.
[00180] To form a source of pyruvic acid, 250 μl of pyruvic acid are sorbed by capillarity into a first sintered porous plastic plug with a length of 10 mm and a density of 0.33g/cm3 having a core of polyethylene terephthalate (PET) ) and a polyethylene (PE) sheath and 100 μl of pyruvic acid are sorbed by capillarity into a second sintered porous plastic plug with a length of 10 mm and a density of 0.3g/cm3 with a core of polyethylene terephthalate ( PET) and a polyethylene (PE) sheath and a viscose B fiber fill and lower air permeability than the first sintered porous plastic plug. A suitable first plastic porous plug is Porex® XMF-0507 (available from Porex GmbH, Germany) and a second suitable plastic sintered porous plug is Porex® XMF-0130+B (available from Porex GmbH, Germany).
[00181] To form a source of nicotine, 10 μl of nicotine is sorbed by means of capillarity into a sintered porous plastic plug with a length of 50 mm and a density of 0.33 g/cm3, having a core of polyethylene terephthalate ( PET) and a polyethylene (PE) sheath. A suitable porous plastic plug is Porex® XMF-0507 (available from Porex® Technologies GmbH, Germany).
[00182] An aerosol generating article according to the invention, with construction as shown in Figure 1(b) is assembled comprising the source of pyruvic acid and the source of nicotine. The second sintered plastic pyruvic acid source plug is positioned immediately downstream of and abutting the first sintered plastic pyruvic acid source plug and the nicotine source is positioned 10 mm downstream of the second plastic plug porous sinter from the source of pyruvic acid.
[00183] To form a source of pyruvic acid 250 μl of pyruvic acid are wick sorbed into a first sintered porous plastic plug with a length of 10 mm and a density of 0.33g/cm3 having a core of polyethylene terephthalate (PET) ) and a polyethylene (PE) sheath and 100 μl of pyruvic acid are sorbed by capillarity into a second sintered porous plastic plug with a length of 10 mm and a density of 0.15g/cm3 with a core of polyethylene terephthalate (PET) ) and a polyethylene (PE) sheath and a viscose B fiber fill and lower air permeability than the first sintered porous plastic plug. A suitable first plastic porous plug is Porex® XMF-0507 (available from Porex GmbH, Germany) and a second suitable plastic sintered porous plug is Porex® XMF-0130+B (available from Porex GmbH, Germany).
[00184] To form a source of nicotine, 10 μl of nicotine is sorbed by means of capillarity into a sintered porous plastic plug with a length of 50 mm and a density of 0.33 g/cm3, having a core of polyethylene terephthalate ( PET) and a polyethylene (PE) sheath. A suitable porous plastic plug is Porex® XMF-0507 (available from Porex® Technologies GmbH, Germany).
[00185] An aerosol generating article according to the invention with construction as shown in Figure 1(b) is assembled comprising the source of pyruvic acid and the source of nicotine. The second sintered plastic pyruvic acid source plug is positioned immediately downstream of and abutting the first sintered plastic pyruvic acid source plug and the nicotine source is positioned 10 mm downstream of the second plastic plug porous sinter from the source of pyruvic acid.
[00186] To form a source of pyruvic acid, 320 μl of pyruvic acid are sorbed by capillarity into a first sintered porous plastic plug with a length of 10 mm and a density of 0.3g/cm3 having a core of polyethylene terephthalate (PET) ), a polyethylene (PE) sheath and a sintered viscose B fiber fill and 100 μl of pyruvic acid are sorbed by capillarity into a second sintered porous plastic plug with a length of 10 mm and a density of 0.33g/cm3 with a core of polyethylene terephthalate (PET) and a sheath of polyethylene terephthalate (PET) and lower air permeability than the first sintered porous plug. A suitable first plastic porous plug is Porex® XMF-130+B (available from Porex GmbH, Germany) and a second suitable plastic sintered porous plug is Porex® XMF-607 (available from Porex GmbH, Germany).
[00187] To form a source of nicotine, 10 μl of nicotine is sorbed by means of capillarity into a sintered porous plastic plug with a length of 50 mm and a density of 0.33 g/cm3, having a core of polyethylene terephthalate ( PET) and a polyethylene (PE) sheath. A suitable porous plastic plug is Porex® XMF-0507 (available from Porex® Technologies GmbH, Germany).
[00188] An aerosol generating article according to the invention with construction as shown in Figure 1(b) is assembled comprising the source of pyruvic acid and the source of nicotine. The second sintered plastic pyruvic acid source plug is positioned immediately downstream of and abutting the first sintered plastic pyruvic acid source plug and the nicotine source is positioned 10 mm downstream of the second plastic plug porous sinter from the source of pyruvic acid.
[00189] To form a source of pyruvic acid, 320 μl of pyruvic acid are sorbed by capillarity into a first sintered porous plastic plug with a length of 10 mm and a density of 0.15g/cm3 having a core of polyethylene terephthalate (PET) ), a polyethylene (PE) sheath and a sintered viscose B fiber fill and 100 μl of pyruvic acid are sorbed by capillarity into a second sintered porous plastic plug with a length of 10 mm and a density of 0.33g/cm3 with a core of polyethylene terephthalate (PET) and a sheath of polyethylene terephthalate (PET) and lower air permeability than the first sintered porous plug. A suitable first plastic porous plug is Porex® XMF-130+B (available from Porex GmbH, Germany) and a second suitable plastic sintered porous plug is Porex® XMF-607 (available from Porex GmbH, Germany).
[00190] To form a source of nicotine, 10 μl of nicotine is sorbed by means of capillarity in a sintered porous plastic plug with a length of 50 mm and a density of 0.33g/cm3, having a core of polyethylene terephthalate ( PET) and a polyethylene (PE) sheath. A suitable porous plastic plug is Porex® XMF-0507 (available from Porex® Technologies GmbH, Germany).
[00191] An aerosol generating article according to the invention with construction as shown in Figure 1(b) is assembled comprising the source of pyruvic acid and the source of nicotine. The second sintered plastic pyruvic acid source plug is positioned immediately downstream of and abutting the first sintered plastic pyruvic acid source plug and the nicotine source is positioned 10 mm downstream of the second plastic plug porous sinter from the source of pyruvic acid.
[00192] The nicotine yield per group of five puffs of the aerosol generating articles of comparative example (a) and examples (b) to (g) is measured under a Health Canada smoking regimen over 30 puffs with a volume 55 ml puff, 2 second puff duration and a 30 second puff interval. Each group of five puffs is collected on a Cambridge filter pad and then extracted with a liquid solvent. The resulting liquid is analyzed by gas chromatography to determine the nicotine distribution. The results are shown in Figures 2, 3 and 4.
[00193] As used in Figure 2, the nicotine delivery of puffs 6-10, 11-15, 16-20, 21-25 and 26-30 of the aerosol generating articles according to examples (b) and ( c) is greater than that of the corresponding puffs of the prior art aerosol generating article of comparative example (a). As a result, the inclusion in the aerosol generating articles according to the invention of examples (b) and (c) of a source of pyruvic acid comprising a first porous sorption element and a second porous sorption element downstream of the first sorption element, where the release rate of pyruvic acid from the first sorption element is greater than the release rate of the second sorption element, advantageously results in more consistent and sustained nicotine delivery when compared to the article prior art aerosol generator of comparative example (a).
[00194] As shown in Figures 3 and 4, the property change of the first sorption element and the second sorption element and therefore the difference in the rate of release of pyruvic acid from the first sorption element and the second sorption element, enables the nicotine delivery of the aerosol generating articles according to the invention of examples (b) to (g) to be controlled.
[00195] The invention has been exemplified above with reference to aerosol generating articles which comprise sources of delivery enhancing compound which comprise porous plastic plugs with pyruvic acid adsorbed thereon and medicament sources which comprise porous plastic plugs having nicotine adsorbed thereon. about yourself. However, it will be understood that aerosol generating articles and aerosol generating systems according to the invention may comprise other sorption elements, other delivery enhancing compounds and other medicaments.

权利要求:
Claims (21)
[0001]
1. Aerosol generating system characterized in that it comprises: a drug source (20); and a source of volatile distribution enhancing compound (10), this source of volatile distribution enhancing compound comprising: a first sorption element (30); a second sorption element (40) downstream of the first sorption element; and a volatile delivery enhancement compound sorbed on the first sorption element and the second sorption element, wherein the release rate of the volatile delivery enhancement compound from the first sorption element is greater than the release rate of the enhancement compound of volatile distribution from the second sorption element.
[0002]
2. Aerosol generating system according to claim 1, characterized in that the air permeability of the first sorption element is greater than the air permeability of the second sorption element.
[0003]
3. Aerosol generating system according to claim 1 or 2, characterized in that the porosity of the first sorption element is greater than the porosity of the second sorption element.
[0004]
4. Aerosol generating system according to claim 1, 2 or 3, characterized in that the polarity of the second sorption element is greater than the polarity of the first sorption element.
[0005]
5. Aerosol generating system according to any one of claims 1 to 4, characterized in that the drug source comprises: a third sorption element (50); and a drug sorbed on the third sorption element.
[0006]
6. Aerosol generating system according to claim 5, characterized in that the drug comprises nicotine.
[0007]
7. An aerosol generating system according to any one of claims 1 to 6, characterized in that the volatile delivery enhancing compound comprises an acid.
[0008]
8. Aerosol generating system according to claim 7, characterized in that the acid is selected from the group consisting of 3-methyl-2-oxovaleric acid, pyruvic acid, 2-oxovaleric acid, 4-methyl-2- oxovaleric, 3-methyl-2-oxobutanoic acid, 2-oxo-octanoic acid and combinations thereof.
[0009]
9. Aerosol generating system according to claim 8, characterized in that the acid is a pyruvic acid.
[0010]
10. An aerosol generating system according to any one of claims 1 to 9, characterized in that the amount of volatile distribution-enhancing compound sorbed onto the first sorption element is greater than the amount of volatile distribution-enhancing compound sorbed on the second sorption element.
[0011]
11. Aerosol generating system according to any one of claims 1 to 10, characterized in that the first sorption element has substantially the same dimensions as the second sorption element.
[0012]
12. Aerosol generating system according to any one of claims 1 to 11, characterized in that the second sorption element is immediately downstream of and in contact with the first sorption element.
[0013]
13. Aerosol generating system according to any one of claims 1 to 11, characterized in that the second sorption element is spaced from the first sorption element.
[0014]
14. Aerosol generating system according to any one of claims 1 to 13, characterized in that it comprises: an aerosol generating article comprising the drug source and the volatile delivery-enhancing compound source.
[0015]
15. Aerosol generating system according to claim 14, characterized in that it further comprises: an aerosol generating device in cooperation with the aerosol generating article, the aerosol generating device comprising heating means for heating one or both of the drug source and the volatile delivery enhancing compound source of the aerosol generating article.
[0016]
16. Aerosol generating article, characterized in that it is for use in an aerosol generating system as defined in claim 14 or 15.
[0017]
17. Aerosol generating article according to claim 16, characterized in that it comprises a housing comprising: an air inlet; a first compartment in communication with the air inlet, the first compartment comprising a first of the source of drug and the source of volatile delivery-enhancing compound; a second compartment in communication with the first compartment, the second compartment comprising a second of the source of drug and the source of volatile delivery-enhancing compound; and an air outlet, in which the air inlet and air outlet are in communication with each other, and configured so that air can pass into the housing through the air inlet, through the housing and out of the housing. housing through the air outlet.
[0018]
18. Aerosol generating article according to claim 16, characterized in that it comprises a housing comprising: an air inlet; a first compartment in communication with the air inlet, the first compartment comprising one of the first drug source and the first volatile delivery-enhancing compound source; a second compartment in communication with the air inlet, the second compartment comprising a second of the drug source and the volatile delivery-enhancing compound source; and an air outlet, in which the air inlet and air outlet are in communication with each other and configured so that air can pass into the housing through the air inlet, through the housing and out of the housing through the air outlet.
[0019]
19. Aerosol generating article according to claim 16, characterized in that it comprises a housing comprising: a first air inlet; a second air inlet; a first compartment in communication with the first air inlet, the first compartment comprising a first of the drug source and the source of volatile delivery-enhancing compound; a second compartment in communication with the second air inlet, the second compartment comprising a second of the drug source and the source of drug-enhancing compound. volatile distribution; and an air outlet, wherein the first air inlet, second air inlet and air outlet are in communication with each other and are configured so that air can pass into the housing through the first air inlet, through from the housing and out of the housing through the air outlet and so that air can pass inside the housing through the second air inlet, through the housing and out of the housing through the air outlet.
[0020]
An aerosol generating article according to any one of claims 17 to 19, characterized in that one or both of the first compartment and the second compartment of the aerosol generating article are sealed by one or more fragile seals.
[0021]
An aerosol generating article according to any one of claims 17 to 20, characterized in that the first compartment comprises the source of volatile delivery-enhancing compound and the second compartment comprises the source of medicament.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112015027149B1|2022-01-11|AEROSOL GENERATING SYSTEM COMPRISING A SOURCE OF DISTRIBUTION IMPROVEMENT COMPOUND AND A SOURCE OF DRUG

---

US11246998B2|2022-02-15|Aerosol-generating system with differential heating

---

JP2019162148A|2019-09-26|Electrically heated aerosol delivery system

---

BR112016011058B1|2021-08-31|AEROSOL GENERATING SYSTEM TO GENERATE AND CONTROL THE AMOUNT OF NICOTINE SALT PARTICLES

同族专利:

---

公开号 | 公开日

---

ES2630715T3|2017-08-23|

---

PH12015502176A1|2016-01-25|

---

NZ712478A|2018-08-31|

---

JP6416226B2|2018-10-31|

---

TW201524381A|2015-07-01|

---

KR20160013006A|2016-02-03|

---

JP2016523595A|2016-08-12|

---

BR112015027149A2|2017-07-25|

---

AU2014270525A1|2015-11-05|

---

AR096354A1|2015-12-23|

---

SI2999507T1|2017-06-30|

---

LT2999507T|2017-06-12|

---

EP2999507A1|2016-03-30|

---

WO2014187763A1|2014-11-27|

---

MX2015016074A|2016-03-21|

---

HUE031929T2|2017-08-28|

---

RS55992B1|2017-09-29|

---

CA2910548C|2021-06-22|

---

AU2014270525B2|2018-06-14|

---

CN105188817B|2019-01-18|

---

CN105188817A|2015-12-23|

---

HK1218088A1|2017-02-03|

---

SG11201508669UA|2015-11-27|

---

RU2015154179A3|2018-03-27|

---

PL2999507T3|2017-08-31|

---

RU2665190C2|2018-08-28|

---

MX368590B|2019-10-08|

---

UA117013C2|2018-06-11|

---

US20160120220A1|2016-05-05|

---

EP2999507B1|2017-04-19|

---

TWI671020B|2019-09-11|

---

KR102276040B1|2021-07-13|

---

ZA201506934B|2017-02-22|

---

PT2999507T|2017-07-13|

---

CA2910548A1|2014-11-27|

---

MY178840A|2020-10-20|

---

RU2015154179A|2017-06-22|

---

IL241811A|2019-08-29|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4830028A|1987-02-10|1989-05-16|R. J. Reynolds Tobacco Company|Salts provided from nicotine and organic acid as cigarette additives|

---

DE3884246T2|1987-02-10|1994-03-03|Reynolds Tobacco Co R|Cigarette.|

---

GB8819291D0|1988-08-12|1988-09-14|British American Tobacco Co|Improvements relating to smoking articles|

---

US4898190A|1989-03-01|1990-02-06|R. J. Reynolds Tabacco Company|Adjustable air dilution cigarette with pressure drop compensation|

---

EP0539674B1|1991-10-19|1996-06-12|Solvay Deutschland GmbH|Aerosol generating system|

---

US5546965A|1994-06-22|1996-08-20|R. J. Reynolds Tobacco Company|Cigarette with improved fuel element insulator|

---

US6196218B1|1999-02-24|2001-03-06|Ponwell Enterprises Ltd|Piezo inhaler|

---

CA2540831A1|2003-10-21|2005-06-02|Vapore, Inc.|Improved capillary pumps for vaporization of liquids|

---

AU2003270320B2|2002-09-06|2008-10-23|Philip Morris Products S.A.|Aerosol generating device and method of use thereof|

---

JP2008035742A|2006-08-03|2008-02-21|British American Tobacco Pacific Corporation|Evaporating apparatus|

---

EP2708256A3|2007-03-30|2014-04-02|Philip Morris Products S.A.|Device and method for delivery of a medicament|

---

MY177136A|2009-03-17|2020-09-08|Philip Morris Products Sa|Tobacco-based nicotine aerosol generation system|

---

AU2010295883B2|2009-09-16|2015-08-20|Philip Morris Products Sa|Improved device and method for delivery of a medicament|

---

EP2399636A1|2010-06-23|2011-12-28|Philip Morris Products S.A.|An improved aerosol generator and liquid storage portion for use with the aerosol generator|

---

UA115426C2|2011-09-09|2017-11-10|Філіп Морріс Продактс С.А.|Smoking article filter including polymeric insert|US10244793B2|2005-07-19|2019-04-02|Juul Labs, Inc.|Devices for vaporization of a substance|

---

US10279934B2|2013-03-15|2019-05-07|Juul Labs, Inc.|Fillable vaporizer cartridge and method of filling|

---

US10517530B2|2012-08-28|2019-12-31|Juul Labs, Inc.|Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances|

---

JP6400678B2|2013-05-06|2018-10-03|ジュール・ラブズ・インコーポレイテッドＪｕｕｌ Ｌａｂｓ， Ｉｎｃ．|Nicotine salt formulation for aerosol device and method thereof|

---

CN105473012B|2013-06-14|2020-06-19|尤尔实验室有限公司|Multiple heating elements with individual vaporizable materials in electronic vaporization devices|

---

US10039321B2|2013-11-12|2018-08-07|Vmr Products Llc|Vaporizer|

---

US10463069B2|2013-12-05|2019-11-05|Juul Labs, Inc.|Nicotine liquid formulations for aerosol devices and methods thereof|

---

US10076139B2|2013-12-23|2018-09-18|Juul Labs, Inc.|Vaporizer apparatus|

---

US20160366947A1|2013-12-23|2016-12-22|James Monsees|Vaporizer apparatus|

---

US10159282B2|2013-12-23|2018-12-25|Juul Labs, Inc.|Cartridge for use with a vaporizer device|

---

US10058129B2|2013-12-23|2018-08-28|Juul Labs, Inc.|Vaporization device systems and methods|

---

HUE053511T2|2013-12-23|2021-07-28|Juul Labs Int Inc|Vaporization device systems|

---

US10512282B2|2014-12-05|2019-12-24|Juul Labs, Inc.|Calibrated dose control|

---

US11154668B2|2015-02-06|2021-10-26|Philip Morris Products S.A.|Containers for aerosol-generating devices|

---

GB201511359D0|2015-06-29|2015-08-12|Nicoventures Holdings Ltd|Electronic vapour provision system|

---

GB201511349D0|2015-06-29|2015-08-12|Nicoventures Holdings Ltd|Electronic aerosol provision systems|

---

GB201511358D0|2015-06-29|2015-08-12|Nicoventures Holdings Ltd|Electronic aerosol provision systems|

---

EP3393283B1|2015-12-22|2020-02-05|Philip Morris Products S.a.s.|A cartridge for an aerosol-generating system and an aerosol-generating system comprising a cartridge|

---

EP3183980B1|2015-12-22|2018-08-08|Philip Morris Products S.a.s.|A cartridge for an aerosol-generating system and an aerosol-generating system comprising a cartridge|

---

MX2018007311A|2015-12-22|2018-09-11|Philip Morris Products Sa|A cartridge for an aerosol-generating system and an aerosol-generating system comprising a cartridge.|

---

SG11201806801VA|2016-02-11|2018-09-27|Juul Labs Inc|Securely attaching cartridges for vaporizer devices|

---

DE202017007467U1|2016-02-11|2021-12-08|Juul Labs, Inc.|Fillable vaporizer cartridge|

---

US10405582B2|2016-03-10|2019-09-10|Pax Labs, Inc.|Vaporization device with lip sensing|

---

USD849996S1|2016-06-16|2019-05-28|Pax Labs, Inc.|Vaporizer cartridge|

---

USD851830S1|2016-06-23|2019-06-18|Pax Labs, Inc.|Combined vaporizer tamp and pick tool|

---

USD836541S1|2016-06-23|2018-12-25|Pax Labs, Inc.|Charging device|

---

USD848057S1|2016-06-23|2019-05-07|Pax Labs, Inc.|Lid for a vaporizer|

---

USD842536S1|2016-07-28|2019-03-05|Juul Labs, Inc.|Vaporizer cartridge|

---

USD825102S1|2016-07-28|2018-08-07|Juul Labs, Inc.|Vaporizer device with cartridge|

---

USD887632S1|2017-09-14|2020-06-16|Pax Labs, Inc.|Vaporizer cartridge|

---

KR20200030364A|2018-09-12|2020-03-20|주식회사 케이티앤지|Composite heat source, and smoking article comprising the composite hear source|

---

US11235110B1|2020-07-29|2022-02-01|Gregory Ellis|Delivery system for ayahuasca-like substances|

法律状态:
2018-11-06| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2020-01-14| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-07-13| B350| Update of information on the portal [chapter 15.35 patent gazette]|

---

2021-10-26| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2022-01-11| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2014, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP13168613.1|2013-05-21|

---

EP13168613|2013-05-21|

---

PCT/EP2014/060204|WO2014187763A1|2013-05-21|2014-05-19|Aerosol comprising distributing agent and a medicament source|

---